4.7 Article

Nopp140-chaperoned 2′-O-methylation of small nuclear RNAs in Cajal bodies ensures splicing fidelity

期刊

GENES & DEVELOPMENT
卷 35, 期 15-16, 页码 1123-+

出版社

COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gad.348660.121

关键词

Cajal bodies; RNA modification; casein kinase 2; nuclear organization; phosphorylation; pre-mRNA splicing; scaRNPs; snRNA; snoRNPs

资金

  1. National Institutes of Health (NIH) [P30CA013330]
  2. NIH-funded Shared Instrumentation Grant [S10OD016214]
  3. NIH [HL136662, R01 GM33397]
  4. Belgian Fonds de la Recherche Scientifique (FRS/FNRS)
  5. Universite Libre de Bruxelles (ULB)
  6. European Joint Programme on Rare Diseases
  7. Region Wallonne (SPW EER)
  8. Internationale Brachet Stiftung
  9. Epitran COST action [CA16120]

向作者/读者索取更多资源

The research reveals the crucial role of protein Nopp140 in Cajal bodies and its mechanism of targeting to CBs through phosphorylation by casein kinase 2. Passing through CBs, snRNAs are modified by scaRNPs, and these modifications play a key role in splicing accuracy.
Spliceosomal small nuclear RNAs (snRNAs) are modified by small Cajal body (CB)-specific ribonucleoproteins (scaRNPs) to ensure snRNP biogenesis and pre-mRNA splicing. However, the function and subcellular site of snRNA modification are largely unknown. We show that CB localization of the protein Nopp140 is essential for concentration of scaRNPs in that nuclear condensate; and that phosphorylation by casein kinase 2 (CK2) at similar to 80 serines targets Nopp140 to CBs. Transiting through CBs, snRNAs are apparently modified by scaRNPs. Indeed, Nopp140 knockdown-mediated release of scaRNPs from CBs severely compromises 2'-O-methylation of spliceosomal snRNAs, identifying CBs as the site of scaRNP catalysis. Additionally, alternative splicing patterns change indicating that these modifications in U1, U2, U5, and U12 snRNAs safeguard splicing fidelity. Given the importance of CK2 in this pathway, compromised splicing could underlie the mode of action of small molecule CK2 inhibitors currently considered for therapy in cholangiocarcinoma, hematological malignancies, and COVID-19.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据